Finnegan, Women's Health Initiative Program Office, 7550 Rockville Pike, Room 6A09, Bethesda, Maryland 20892–9110 or call non-toll-free number (301) 402–2900, or E-mail your request, including your address to: <FinnegaL@od31em1.od.nih.gov>.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before January 3, 1997.

Dated: October 23, 1996.

Stephen Benowitz,

Executive Officer, OD.

[FR Doc. 96–28273 Filed 11–1–96; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for B-Cell Lymphoma Tumor Specific Antigen Studies

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks a Cooperative Research and Development Agreement (CRADA) with a pharmaceutical or biotechnology company. A major goal of the CRADA is to develop strategies to isolate B-cell lymphoma tumor specific antigen. The CRADA would have an expected duration of one (1) to five (5) years. The goals of the CRADA include the rapid publication of research results and the timely commercialization of any products, diagnostics and treatments that result from the research.

ADDRESSES: Proposals and questions about this CRADA opportunity may be addressed to Gary Cuchural, Office of Technology Development, National Cancer Institute-Frederick Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702–1201, Telephone: (301) 846–5465, Facsimile: (301) 846–6820.

EFFECTIVE DATE: In view of the high interest in developing Anti-Cancer Vaccines in general, interested parties should notify the NCI Office of Technology Development in writing no later than December 4, 1996.

SUPPLEMENTARY INFORMATION: A major research goal of this CRADA is the development of strategies for the isolation of lymphoma derived Ig protein, including for example, the molecular cloning of Ig variable regions for expression in eukaryotic and prokaryotic cells. Another major research goal of this CRADA is the development and implementation of procedures for the GMP production of Ig protein. GMP Ig protein will be produced in sufficient quantities to support vaccine formulation studies. Vaccine formulation studies with one of several carriers, final vaccine production, and/or testing may also be among the research goals of this CRADA.

The role of the National Cancer Institute in this CRADA will include, but not be limited to:

1. Providing intellectual, scientific, and clinical expertise and experience to the research project.
2. Planning and conducting research studies and interpreting research results.
3. Publishing research results.

The role of the CRADA Collaborator may include, but not be limited to:

1. Providing intellectual, scientific, and regulatory expertise and experience to the research project.
2. Planning and conducting research studies and interpreting research results.
3. Providing support for CRADA-related research. Such support may include personnel and/or financial support to facilities scientific goals. Such support should include the availability of GMP manufacturing facilities for this effort, such support should also include assuming the cost of production of GMP Ig protein in sufficient quantities to support vaccine formulation studies. If vaccine formulation studies with one of several carriers, final vaccine production and/or testing are among the research goals of this CRADA, such support should also include assuming the cost of production of GMP vaccines in sufficient quantities to support these goals.
4. The experience and financial ability to support an IND.
5. Publishing research results.

Selection criteria for choosing the CRADA Collaborator may include, but not to be limited to:

1. The ability to collaborate with NCI on research and development of this technology. This ability can be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development.
2. The demonstration of adequate resources to perform the research, development and commercialization of this technology (e.g. facilities, personnel and expertise) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.
3. The willingness to commit best effort and demonstrated resources to the research, development and commercialization of this technology.
4. The demonstration of expertise in the commercial development, GMP production, marketing and sales of patient-specific products related to this area of technology.
5. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities.
6. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.
7. The agreement to be bound by the appropriate DHHS regulations relating to human subjects, and all PHS policies relating to the use and care of laboratory animals.
8. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the equitable distribution of patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor, with (1) the grant of a non-exclusive license to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect and exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor.

Dated: October 24, 1996.

Thomas D. Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 96–28275 Filed 11–1–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent applications referenced below may be obtained by